RxDoctor Payments Data

Jennifer Lashley, PA

Physician Assistant · Greenville, SCNPI 1336323401

Payments from drug & device makers

$5,051in general payments, 2019–2025

Across 213 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$1K
  • Electromed, Inc.$476
  • GSK$432
  • AstraZeneca$315
  • Boehringer Ingelheim$258
  • Jazz Pharmaceuticals Inc.$214
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$84017%
  • Food & beverage$4,21183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,051 in reported general payments places this provider in the 90th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$35,184
Medicare patients
349
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$79,201
Breo ElliptaFluticasone/Vilanterol29$15,793
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$11,003
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,089
Incruse ElliptaUmeclidinium Bromide14$5,238
Albuterol Sulfate HfaAlbuterol Sulfate105$3,058
SymbicortBudesonide/Formoterol Fumarate12$2,764
Modafinil13$389
Ropinirole Hcl20$371
Temazepam41$329
Trazodone Hcl91$319
Zaleplon14$272
Desloratadine13$265
Fluticasone Propionate21$257
Gabapentin23$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$432$111,235135 claims
Boehringer IngelheimStiolto Respimat$258$6,08913 claims
AstraZenecaSymbicort$315$2,76412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →